4-氯-8-(三氟甲基)-3-喹啉腈 | 157301-82-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氯-8-(三氟甲基)-3-喹啉腈
• 英文名称: 4-chloro-8-(trifluoromethyl)quinoline-3-carbonitrile
• CAS: 157301-82-1
• 化学式: C₁₁H₄ClF₃N₂
• 分子量: 256.614
• InChiKey: AECGTVCPQODZIE-UHFFFAOYSA-N

物化性质

• 沸点：
  349.2±37.0 °C(Predicted)
• 密度：
  1.50±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-氯-8-(三氟甲基)-3-喹啉腈 在 四(三苯基膦)钯 三乙酰氧基硼氢化钠 、 sodium carbonate 、 溶剂黄146 作用下， 以 四氢呋喃 、 乙醇 、 水 、 甲苯 为溶剂， 反应 3.0h， 生成 2-{4-[({3-[3-Cyano-8-(trifluoromethyl)quinolin-4-yl]phenyl}amino)methyl]phenyl}acetic acid
  参考文献：
  名称：

  Further modification on phenyl acetic acid based quinolines as liver X receptor modulators

  摘要：

  A series of phenyl acetic acid based quinolines was prepared as LXR modulators. An SAR study in which the C-3 and C-8 positions of the quinoline core were varied led to the identification of two potent LXR agonists 23 and 27. Both compounds displayed good binding affinity for LXR beta and LXR alpha, and increased expression of ABCAl in THP-1 cells. These two compounds also had desirable pharmacokinetic profiles in mice and displayed in vivo efficacy in a 12-week Apo E knockout mouse lesion model. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.03.013
• 作为产物：
  描述：

  邻氨基三氟甲苯 在 三氯氧磷 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 4-氯-8-(三氟甲基)-3-喹啉腈
  参考文献：
  名称：

  Further modification on phenyl acetic acid based quinolines as liver X receptor modulators

  摘要：

  A series of phenyl acetic acid based quinolines was prepared as LXR modulators. An SAR study in which the C-3 and C-8 positions of the quinoline core were varied led to the identification of two potent LXR agonists 23 and 27. Both compounds displayed good binding affinity for LXR beta and LXR alpha, and increased expression of ABCAl in THP-1 cells. These two compounds also had desirable pharmacokinetic profiles in mice and displayed in vivo efficacy in a 12-week Apo E knockout mouse lesion model. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.03.013

文献信息

• Quinolines useful in treating cardiovascular disease
  申请人：Collini D. Michael

  公开号：US20050131014A1

  公开（公告）日：2005-06-16

  This invention provides compounds of formula I that are useful in the treatment or inhibition of LXR mediated diseases.

  本发明提供了式I化合物的用途，它们在治疗或抑制LXR介导的疾病中是有用的。
• Quinoline-3-carboxamide containing sulfones as liver X receptor (LXR) agonists with binding selectivity for LXRβ and low blood–brain penetration
  作者：Baihua Hu、Ron Bernotas、Rayomand Unwalla、Michael Collini、Elaine Quinet、Irene Feingold、Annika Goos-Nilsson、Anna Wilhelmsson、Ponnal Nambi、Mark Evans、Jay Wrobel

  DOI：10.1016/j.bmcl.2009.11.062

  日期：2010.1

  A series of quinoline-3-carboxamide containing sulfones was prepared and found to have good binding affinity for LXRβ and moderate binding selectivity over LXRα. The 8-Cl quinoline analog 33 with a high TPSA score, displayed 34-fold binding selectivity for LXRβ over LXRα (LXRβ IC50 = 16 nM), good activity for inducing ABCA1 gene expression in a THP macrophage cell line, desired weak potency in the

  制备了一系列包含喹啉-3-甲酰胺的砜，发现它们具有对LXRβ的良好结合亲和力和对LXRα的中等结合选择性。TPSA得分高的8-Cl喹啉类似物33对LXRβ的结合选择性超过LXRα的34倍（LXRβIC 50  = 16 nM），在THP巨噬细胞系中诱导ABCA1基因表达的活性良好，所需的弱效LXRαGal4功能测定和低血脑屏障穿透力在大鼠中。
• Quinolines and pharmaceutical compositions thereof
  申请人：Wyeth

  公开号：US07576215B2

  公开（公告）日：2009-08-18

  This invention provides compounds of formula I that are useful in the treatment or inhibition of LXR mediated diseases.

  本发明提供了I式化合物，可用于治疗或抑制LXR介导的疾病。
• QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE
  申请人：Wyeth, A Corporation of the State of Delaware

  公开号：EP1692111A2

  公开（公告）日：2006-08-23
• US7576215B2
  申请人：——

  公开号：US7576215B2

  公开（公告）日：2009-08-18